AARD · Aardvark Therapeutics, Inc.
$6.82
+0.93 (+15.79%)
At close · Aug 21
Market Cap
$149.25M
Shares
21.88M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.82
Open$5.91
Day$5.80–6.90
52W close$3.48–17.41
Avg vol 30d166K
Short int652K · 3.0% float · 4.5d
Short vol31%
DataFeb 2025–Aug 2026
Filing10-Q · Aug 11
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 11, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Sell
Momentum
Strong
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.51
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−17%
below
Price vs 50-day avg
+16%
above
RSI (14)
53
neutral
MACD trend
Negative
52-week position
24%
mid-range
Momentum
relative strength
1-month return
+8%
trailing
6-month return
+25%
trailing
YTD return
−48%
this year
Relative strength
+13%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $6 › 200d $8 — 200d above 50d
Institutional flow
Distributing
-10% holders QoQ · +18 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.98% of float · ▲ +0.1% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
72 holders — mid 1-yr range
Squeeze score
54
elevated · 0–100
Fundamentals
EPS growth
+43%
Y/Y
Free cash flow
$-54.3M
Balance sheet
$47.1M
net cash
Quant / Vol
risk profile
Volatility
128%
annualized · 1-yr
Max drawdown
−80%
past year
ATR
12.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−17%
Bearish
Price vs 50-day avg
+16%
Bullish
RSI (14)
53
Neutral
MACD trend
Negative
Bearish
52-week position
24%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $6 › 200d $8 — 200d above 50d
Institutional flow
Distributing
-10% holders QoQ · +18 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.98% of float · ▲ +0.1% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
72 holders — mid 1-yr range
Price context
position in its 52-week range
Range low $3
Now $7 · 24%
Range high $17
vs 200-day avg -17%
vs 50-day avg +16%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AARD
this stock
Aardvark Therapeutics, Inc.
|
$149.25M | -48.0% | — | — | 3.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.91B | +20.9% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.87B | +8.1% | +20.8% | 20.7 | 3.3% |
|
ARGX
Argenx SE
|
$64.66B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$57.97B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AARD | +4.3% | +7.9% | +24.7% | +3.3% | -48.0% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +5.7% | +4.3% | +13.1% | +0.8% | -60.3% |
Key facts
CIK
1774857
CUSIP
002942100
13F (30d)
63 filings
63 filers
Visit website
Investor relations